Reviewing Madrigal Pharmaceuticals Inc. (MDGL)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – MS Wkly

We will be contrasting the differences between Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) as far as profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows us the return on assets, return on equity and net margins of both companies.

Volatility & Risk

Madrigal Pharmaceuticals Inc.s current beta is 1.16 and it happens to be 16.00% more volatile than Standard & Poors 500. Brainstorm Cell Therapeutics Inc.s 1.19 beta is the reason why it is 19.00% more volatile than Standard & Poors 500.

Liquidity

Madrigal Pharmaceuticals Inc. has a Current Ratio of 45.8 and a Quick Ratio of 45.8. Competitively, Brainstorm Cell Therapeutics Inc.s Current Ratio is 1 and has 1 Quick Ratio. Madrigal Pharmaceuticals Inc.s better ability to pay short and long-term obligations than Brainstorm Cell Therapeutics Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for Madrigal Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.

$150.5 is Madrigal Pharmaceuticals Inc.s average target price while its potential upside is 57.59%. Meanwhile, Brainstorm Cell Therapeutics Inc.s average target price is $9, while its potential upside is 147.25%. Based on the results shown earlier, Brainstorm Cell Therapeutics Inc. is looking more favorable than Madrigal Pharmaceuticals Inc., analysts view.

Insider & Institutional Ownership

Institutional investors held 98.9% of Madrigal Pharmaceuticals Inc. shares and 11.4% of Brainstorm Cell Therapeutics Inc. shares. Insiders held roughly 11.33% of Madrigal Pharmaceuticals Inc.s shares. Comparatively, Brainstorm Cell Therapeutics Inc. has 0.6% of its share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Madrigal Pharmaceuticals Inc. has -22.56% weaker performance while Brainstorm Cell Therapeutics Inc. has 12.96% stronger performance.

Summary

Brainstorm Cell Therapeutics Inc. beats Madrigal Pharmaceuticals Inc. on 6 of the 10 factors.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The companys lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor- (THR-) agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It is also developing MGL-3745, which is in pre-clinical stage, a THR- agonist that is in preclinical trials. The company was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Link:
Reviewing Madrigal Pharmaceuticals Inc. (MDGL)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly